Oct 2026· Angewandte Chemie· 0 citations· 41 references
Medicine
TL;DR
P-CHD-TPP is reported, an enzyme-instructed in situ self-assembling probe that triggers PANoptosome-independent PANoptosis via persistent mitochondrial disruption and establishes a mitochondrial sulfenylated protein-labeling strategy that amplifies oxidative stress, providing a paradigm for PANoptosis-based photodynamic-immunotherapy.
Abstract
PANoptosis, an inflammatory programmed cell death that integrates pyroptosis, apoptosis, and necroptosis, holds great promise for cancer immunotherapy. However, conventional strategies relying on PANoptosome assembly are hindered by complex upstream signaling requirements. Here, we report P-CHD-TPP, an enzyme-instructed in situ self-assembling probe that triggers PANoptosome-independent PANoptosis via persistent mitochondrial disruption. Upon alkaline phosphatase (ALP)-triggered dephosphorylation, P-CHD-TPP self-assembles into fluorescent nanoparticles decorated with triphenylphosphonium (TPP) and 1,3-cyclohexanedione (CHD) groups, which are rapidly internalized by tumor cells and preferentially accumulate in mitochondria. The TPP groups in the assembled nanoparticles moderately disrupt mitochondrial homeostasis, leading to protein sulfenylation. Then, the CHD moiety covalently labels and inactivates these sulfenylated proteins, effectively disabling the endogenous reactive oxygen species (ROS) scavenging system. Upon near-infrared irradiation, a massive ROS burst is generated, inflicting severe and sustained mitochondrial damage. This cascade induces rapid PANoptosis-associated pathways and triggers profound mitochondrial DNA release to activate the cGAS-STING pathway. The combined activation elicits robust antitumor immunity, effectively suppressing orthotopic 4T1 tumor growth and prolonging survival. This work establishes a mitochondrial sulfenylated protein-labeling strategy that amplifies oxidative stress, providing a paradigm for PANoptosis-based photodynamic-immunotherapy.
Photodynamic therapy (PDT) is often limited by insufficient oxidative damage and the limited ability of conventional photosensitizers to respond to changes in the intracellular environment. Here, we report a photoresponsive silicon phthalocyanine (AP-SiPc) that enables PDT via microenvironment-dependent self-assembly r...
Xin-Yi Wu, Yi-Chen Xu, Qiu-Hao Ye et al.· Biomaterials Advances· 0 citations
Ferroptosis induced by Fenton-reaction holds great promise in triple-negative breast cancer (TNBC) therapy. However, its efficacy is severely constrained by limited endogenous hydrogen peroxide (H2O2) substrates and poor Fenton reaction efficiency. To overcome these limitations, we propose a strategy to initiate a hete...
Tian-Jiao Zhou, Li-Ling Huang, Hao-Bin Che et al.· Journal of Controlled Releas...· 0 citations
A molecular conformation engineering strategy is developed to construct TBBP, which features a strengthened electron donor, a moderately twisted conformation, extended π-conjugation, and a robust molecular skeleton free of labile olefinic π-bridges, providing a generalizable molecular design principle for the developme...
Xing Wang, Kun-Yan Dong, Zhi-Chao Wang et al.· Advances in Materials· 0 citations
Lysosomes play a crucial role in ferroptosis, presenting a dual opportunity for disease diagnosis and targeted cancer therapy. However, existing lysosomal probes generally lack the photosensitizing capabilities necessary to induce ferroptosis. Herein, we report the development of a novel series of benzimidazole-coumari...
Gan Li, Zhuo-Liang Zhou, Ming-Hao Hu· Analytical Chemistry· 0 citations
Immunogenic cell death (ICD) converts immunosuppressive "cold" tumors into immunogenic "hot" ones, yet ICD inducers with precise tumor-organelle cascade targeting and spatiotemporal controllability remain largely unexplored. Herein, we report a self-delivery nanoplatform (ER-Ru NPs) constructed via the self-assembly of...
Jun Wang, Tao Kuang, Bin Hu et al.· ACS Applied Materials and In...· 0 citations
This work presents a mitochondria-targeted, ROS-activatable supramolecular delivery nanoplatform for self-amplifying redox imbalance and reversing cisplatin resistance for enhanced cisplatin-based cancer therapy.
Ying Liu, Zong-Tao Zhou, Wei Ma et al.· International journal of pha...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.